Uwe Platzbecker
German Cancer Research Center · 1,560 works · 41,037 citations · h-index 89
Top works
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
- Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
- Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
- Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
- Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
- Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
- Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
- P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate
- Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
- A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
- Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
- Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
- Clonal architecture of chronic myelomonocytic leukemias
- Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
- Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
- Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
- Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study
- Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium
- The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML